Austin Medical Technologies, Inc. Adds 14 New Customers in the 3rd Quarter.

PLANO, Texas -- In continuing the strong sales trend from the first of the year, AUSTIN MEDICAL TECHNOLOGIES, Inc. (OTC: AMTK), continues to close more contracts with industry leaders like Island Eye Surgicenter. AMTK added 14 new customers in the same quarter. AMTK continues to build a strong base of customers.

Kurt Tarter, President and CEO, states: "We are very pleased to have Island Eye Surgicenter as a customer. Island Eye is a state of the art surgical facility performing hundreds of surgical procedures monthly while producing outcomes that surpass similar surgery facilities. Island Eye is a recognized leader and strategic landmark center in the north east. Landmark clients like Island Eye lead to our continued strong sales growth. We have just completed a strong sales effort in July and August resulting in 9 new customers. Landmark Surgery centers like Island Eye represent from $50,000.00 to $150,000 of annual sales for both our product lines of LASIK and Cataract surgical kits, typically under contract for 3 to 5 years. We look forward to doing more business with Island Eye in the future."

About Island Eye Surgicenter:

Island Eye Surgicenter is a New York State licensed and Medicare Certified Ambulatory Surgery Center. Unlike other surgery centers, Island Eye is unique in that it specializes in the surgical care and treatment of eye disorders. The center is also a N.Y. State licensed Tissue Transplantation facility, and is a leader in the field of Corneal Transplantation. In addition to it's state licensure, the center has been fully accredited by the AAAHC (Accreditation Association for Ambulatory Health Care) a national organization that monitors compliance with the highest standards in ambulatory health care. www.aahc.org Since opening 3 years ago, Island Eye has established itself as a "Center of Excellence" in surgical eye care. The physician staff is among the most prominent in the country. They contribute significantly to ophthalmic research and literature. Many are recognized as leaders in their field and lecture extensively both nationally and abroad. http://www.islandeye.net/ies-practice.html

About Austin Medical Technologies, Inc./eyeDirecti(TM) (Brand)

Austin Medical Technologies delivers "DIRECT" from the manufacturer to the Surgeon, the only technology based, "Single Source Supply Solution" for custom sterile surgery trays made up of 80% of all disposable surgical devices utilized in surgery. Currently the company has contracted with 200 eye surgery centers including the 2 largest eye surgery centers in the USA. The market for custom sterile surgery trays is a $2.1 Billion market here in the USA.

Austin Medical is dedicated exclusively to the Ambulatory Surgery Center (ASC) market. Ambulatory Surgery Centers (ASC), also called outpatient surgery, and same-day surgery, refers to surgical procedures which are complex enough to require a dedicated operating room and specially trained staff, but do not require an overnight stay. According to 1996 U.S. government statistics, ambulatory surgery centers account for 31 million or 44% of the total surgeries performed in the United States. Five million surgeries were performed on eyes. New surgical techniques such as laser surgery allow procedures to be done more quickly and/or with less surgical trauma.

Under the brand name eyeDirecti, Austin Medical is initially focused on Ophthalmology owned and operated surgery centers which is the fastest growing segment of the ASC market, growing by 25% per annum, consisting of 2,500 practices with 15,000 surgeons performing over 5 million surgical procedures annually at a supply cost of $400,000,000 per year. Austin Medical is positioned to capture $40,000,000 (10%) of this $400,000,000 market within the next 4 years. Visit our e-commerce site at www.eyedirecti.com

Note: Any statements released by Austin Medical Technologies, Inc, or any of its affiliates that are forward- looking, are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act. Editors and investors are cautioned that forward-looking statements invoke risk and uncertainties that may affect the Company's business prospects and performances. These include economic, competitive, governmental, technological and other factors discussed in the statements and in the Company's filings with the Securities and Exchange Commission.